Search

A life outside ophthalmology

Lloyd Paul Aiello. It was an absolute privilege to speak to Lloyd Paul Aiello, Professor of Ophthalmology, Harvard Medical School, and Vice President of Ophthalmology and Director, Beetham Eye Institute, Joslin Diabetes Center, USA. Prof Aiello is a third-generation ophthalmologist,...

The work of RNIB and ECLOs

With more than 2,000,000 people in the UK living with some degree of sight loss and over 300,000 registered as blind or partially sighted, it is important for anyone living with sight loss to know they’re not alone. At what...

WHO SPECS 2030: a global initiative to strengthen refractive error services

Globally, it is estimated that only around one-third of people with vision impairment due to refractive error have received access to a quality pair of spectacles [1]. In recognition that uncorrected refractive error is the leading cause of vision impairment...

In conversation with Prof Carrie MacEwen, Chair of The Way Forward and President, The Royal College of Ophthalmologists

Prof Carrie MacEwen. Scope for optimising capacity within the Hospital Eye Service (HES)? The demand for ophthalmic care continues to grow with no increase in capacity. In order to be able to continue to deliver adequate care ophthalmologists have devised...

In conversation with Iqbal K Ahmed - From across the Atlantic

Ike (Iqbal) K Ahmed is a pioneering ophthalmologist from Canada, currently serving as Assistant Professor at the University of Toronto, and Clinical Assistant Professor at the University of Utah. He is also the Research Fellowship Director, Department of Ophthalmology, University...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...